You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

980 Results
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
May 2024
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Apr 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and No Prior mTOR Inhibitor
New Drug Funding Program
    Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and Prior mTOR Inhibitor
Aug 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
May 2019
Regimen
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Palliative
Nov 2017
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Feb 2023
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Neoadjuvant
May 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer (Second or Subsequent Line)
New Drug Funding Program
    Pembrolizumab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Jan 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI), 
Lung, 
Neuroendocrine (Lung)
Intent: Palliative
Funding:
ODB - General Benefit
    lanreotide
May 2024

Pages